NanoViricides signs agreement for testing of antiviral drug candidates
NanoViricides intends to enter into a master services agreement with LRRI for investigational new drug-enabling efficacy studies of the company's oral FluCide and broad-spectrum injectable drug candidates. The studies would test the drug candidates against multiple influenza subtypes, including the novel H7N9 strain. LRRI would also be able to evaluate NanoViricides' anti-Middle East respiratory syndrome human coronavirus drug candidates.
The NDA allows the scientists of both parties to exchange proprietary and confidential information to prepare for the intended studies.
The FluCide drug is meant for severely ill hospitalized patients and the follow-on oral drug is meant for out-patients.
There are currently no available drugs and vaccines against the MERS-CoV, which was designated a potential threat to public health and national security by President Barack Obama on June 4.
The LRRI is a private, biomedical research organization dedicated to improving public health through research on the treatment, prevention and cure of respiratory disease.
NanoViricides' novel drug candidates are meant to attack enveloped virus particles and dismantle them. The company is developing drugs against multiple viral diseases including seasonal influenza, hepatitis C, dengue fever and Ebola virus.